S&P Healthcare 18,500.00 10.11%
  • Sun Pharmaceutical Industries Ltd. 0000.00
  • Divi’s Laboratories Ltd. 0000.00
  • Cipla Ltd. 0000.00
  • Torrent Pharmaceuticals Ltd. 0000.00
  • Dr. Reddy’s Laboratories Ltd. 0000.00
  • Zydus Lifesciences Ltd. 0000.00
  • Mankind Pharma Ltd. 0000.00
  • Lupin Ltd. 0000.00
  • Aurobindo Pharma Ltd. 0000.00
  • Alkem Laboratories Ltd. 0000.00
  • Glenmark Pharmaceuticals Ltd. 0000.00
  • Natco Pharma Ltd. 0000.00
  • Shilpa Medicare Ltd. 0000.00
  • Ajanta Pharma Ltd. 0000.00
  • J B Chemicals & Pharmaceuticals Ltd. 0000.00
  • Apollo Hospitals Enterprise Ltd. 0000.00
  • Fortis Healthcare Ltd. 0000.00
  • Max Healthcare Institute Ltd. 0000.00
  • Narayana Hrudayalaya Ltd. 0000.00
  • Shalby Ltd. 0000.00
  • Poly Medicure Ltd. 0000.00
  • Medi Assist India Ltd. 0000.00
  • ICICI Lombard General Insurance Company Ltd. 0000.00
  • HDFC Life Insurance Company Ltd. 0000.00
  • SBI Life Insurance Company Ltd. 0000.00
  • Bajaj Finserv Ltd. 0000.00
  • Metropolis Healthcare Ltd. 0000.00
  • Thyrocare Technologies Ltd. 0000.00

SRMIST Signs MoU With CORE Diagnostics to Strengthen Oncology and Genetic Diagnostics Training

SRMIST Signs MoU With CORE Diagnostics to Strengthen Oncology and Genetic Diagnostics Training

The agreement aims to expand student exposure to precision medicine and next-generation genomic technologies amid rising demand for specialized expertise in cancer care.

SRM Institute of Science and Technology (SRMIST) has signed a Memorandum of Understanding (MoU) with CORE Diagnostics to strengthen academic and clinical training in oncology and genetic diagnostics. The agreement aims to expand student exposure to precision medicine and next-generation genomic technologies amid rising demand for specialized expertise in cancer care.

The collaboration is designed to bridge classroom learning with real-world oncology practice by providing students access to advanced diagnostic technologies, genetic counseling frameworks, and industry-led research initiatives. The focus areas include next-generation sequencing, precision oncology, and applied genomic testing.

Cancer care is increasingly shifting toward personalized, data-driven treatment models, where genetic diagnostics play a central role in therapy decisions. With growing adoption of precision-based treatment approaches, institutions are integrating genomic education into healthcare curricula to align with clinical advancements.

Dr. S. Ponnusamy, Registrar of SRMIST, said the partnership would provide students with practical exposure to emerging healthcare domains. “This partnership with CORE Diagnostics will enable our students to gain hands-on experience, benefit from industry expertise, and participate in cutting-edge research in genetic diagnostics and counseling,” he said.

CORE Diagnostics CEO Dinesh Chauhan highlighted the increasing need for trained professionals in cancer diagnostics. He noted that the company operates in 11 countries and handles nearly 1,000 oncology cases daily, bringing clinical and technological expertise to the collaboration. He also emphasized the importance of professionals who understand both the scientific and ethical dimensions of genetic counseling and precision medicine.

Beyond skill development, the MoU provides scope for joint research initiatives focused on advancing cancer diagnostics. The partnership is expected to enhance student competitiveness by combining academic knowledge with applied clinical insight in a rapidly evolving healthcare environment.


Stay tuned for more such updates on Digital Health News

Follow us

More Articles By This Author


Show All